Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aim: Sulphonylureas (SUs) are often used as first‐line treatments for type 2 diabetes in Japan, hence it is important to study new antidiabetic drugs in combination with SUs in Japanese patients. Methods: The efficacy and safety of the once‐daily human glucagon‐like peptide‐1 (GLP‐1) analogue liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m 2 ; mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or glimeprimide) in a 24‐week, double‐blind, parallel‐group trial. Results: The mean change in HBA1c from baseline to week 24 (LOCF) was −1.56 (s.d. 0.84) and −1.46 (s.d. 0.95) with liraglutide 0.9 and 0.6 mg respectively, and −0.40 (s.d. 0.93) with placebo. HBA1c decreased in the placebo group from 8.45 to 8.06%, while liraglutide reduced HBA1c from 8.60 to 7.14%, and from 8.23 to 6.67% at the 0.6 and 0.9 mg doses respectively. Mean HBA1c at week 24 of the two liraglutide groups were significantly lower than the placebo group (p < 0.0001 for both). More subjects reached HBA1c < 7.0% with liraglutide (0.6 mg: 46.5%; 0.9 mg: 71.3%) vs. placebo (14.8%). Fasting plasma glucose (FPG) levels were significantly improved with liraglutide (difference −1.47 mmol/l and −1.80 mmol/l with 0.6 and 0.9 mg vs. placebo; p < 0.0001). Overall safety was similar between treatments: no major hypoglycaemic episodes were reported, while 84/77/38 minor hypoglycaemic episodes occurred in the 0.6 mg/0.9 mg and placebo treatment groups (all in combination with SU), reflecting lower ambient glucose levels. No relevant change in mean body weight occurred in subjects receiving liraglutide (0.6 mg: 0.06 kg; 0.9 mg: −0.37 kg), while mean body weight decreased in subjects receiving placebo (−1.12 kg). Conclusions: The addition of liraglutide to SU treatment for 24 weeks dose‐dependently improved glycaemic control vs. SU monotherapy, without causing major hypoglycaemia or weight gain or loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 3×
“Methods: The efficacy and safety of the once-daily human glucagon-like peptide-1 (GLP-1) analogue liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m2; mean glycated haemoglobin (HBA1c) 8.4”
BackgroundInfluentialHøjberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56 · cited 1×
“In T2DM, the insulin secretion response of beta-cells to physiological levels of GLP-1 is impaired [21], but can be restored with high pharmacological levels of native GLP-1 [22] or with a GLP-1 analogue such as liraglutide [23].”
Background
Research works printed but not linked: 24
- 10.1016/j.diabres.2003.11.024 · DOI · Paper page
- 10.1016/j.metabol.2004.02.012 · DOI · Paper page
- 10.2337/diab.46.1.63 · DOI · Paper page
- 10.1007/s00125-003-1158-9 · DOI · Paper page
- 10.1016/S0140-6736(03)15348-2 · DOI
- Japan Diabetes Society, 2006, Evidence based clinical practice guidelines for the treatment of diabetes mellitus in Japan, J Japan Diab Soc, 49, 409
- Kawamori R., 2003, Efficacy and safety of insulin glargine in concurrent use with oral hypoglycaemic agents for the treatment of type 2 diabetes patients, Rinsho Iyaku, 19, 445
- 10.1016/0168-8227(89)90116-2 · DOI
- Matsuzawa Y, 2002, Atarashii himan nohantei to himanshou no shindan kijun [The new diagnostic criteria of obesity], J Japan Soc Study Obes, 6, 18
- 10.1046/j.1467-789X.2002.00065.x · DOI · Paper page
- 10.1111/j.1464-5491.2006.02022.x · DOI · Paper page
- 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
- 10.2337/diabetes.52.7.1786 · DOI · Paper page
- 10.1016/j.diabres.2008.03.018 · DOI
- 10.1016/j.diabres.2006.01.013 · DOI
- 10.2337/diabetes.48.12.2358 · DOI · Paper page
- 10.1111/j.1600-051X.1988.tb01003.x · DOI · Paper page
- Russell‐Jones D, 2007, Insulin‐associated weight gain in diabetes—causes, effects and coping strategies, Diabetes Obesity Metab, 6, 799, 10.1111/j.1463-1326.2006.00686.x · DOI · Paper page
- 10.1210/jcem.82.12.4460 · DOI · Paper page
- Japan Society for the Study of Obesity, 2004, The Examination Committee of criteria for ‘Obesity Disease’ in Japan, Circ J, 66, 987
- Russell‐Jones D, 2008, The once‐daily human GLP‐1 analog liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline, Diabetes, 57, A593
- Irie S, 2007, Safety, tolerability, pharmacokinetics, and pharmacodynamics of once‐daily GLP‐1 analogue liraglutide in healthy Japanese subjects, Diabetes, 56, A540
- 10.2337/diabetes.51.2.424 · DOI · Paper page
- Seino Y, 2007, Once daily dosing of the long acting GLP‐1 analog liraglutide significantly improves glycaemic control by reducing both fasting and post‐prandial glucose levels in Japanese subjects with type 2 diabetes, Diabetes, 56, A138
Cited by
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Self-citationFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Japanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Metadata
- Authors
- Kaku, K., Rasmussen, M. F., Clauson, P., & Seino, Y.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2010-02-25
- Volume
- 12
- Issue
- 4
- Pages
- 341-347
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2098905490
- Cited by
- 91
- References
- 10
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01194.x
- The paper
- Kaku, K., Rasmussen, M. F., Clauson, P., & Seino, Y. (2010). Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01194.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.